X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

AstraZeneca s Calquence shows superiority to chemotherapy in CLL

Content Team by Content Team
15th June 2019
in Drug Development, News
chemotherapy in CLL

AstraZeneca has announced Calquence (acalabrutinib) reached both its primary and secondary endpoints in chronic lymphocytic leukaemia (CLL).

In preliminary analysis of the Phase III ELEVATE-TN trial Calquence in combination with obinutuzumab caused a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to a chemotherapy combination of chlorambucil and obinutuzumab; this was the primary endpoint of the study.

The drug also reached its secondary endpoint; it demonstrated a statistically significant and clinically meaningful improvement in PFS as a monotherapy compared to the same chemotherapy combination.

Calquence’s safety and tolerability in the ELEVATE-TN trial was consistent with the rest of the drug’s clinical development programme. Full results from the trial will be presented at an upcoming investor meeting.

AstraZeneca Oncology R&D executive vice-president José Baselga said: “These findings confirm the superiority of Calquenceas a monotherapy and also in combination over standard-of-care treatments for chronic lymphocytic leukaemia.

“The positive results from both the ELEVATE-TN and ASCEND trials will serve as the foundation for regulatory submissions later this year.”

Calquence also met its primary endpoint early in the ASCEND trial, results of which were announced in May. In the ASCEND study Calquence was compared to a combination regimen of rituximab plus physician’s choice of idelalisib or bendamustine.

AstraZeneca’s drug showed a statistically-significant and clinically-meaningful improvement in PFS.

In a third ongoing Phase III trial, ELEVATE-RR, Calquence is being investigated in combination with venetoclax in patients with previously-untreated CLL without 17p deletion or TP53 mutation.

Calquence, which is an inhibitor of Bruton tyrosine kinase (BTK), the enzyme that activates B-cells proliferation, trafficking, chemotaxis and adhesion.

The drug is being investigated for a range of B-cell blood cancers, such as diffuse large B-cell lymphoma, Waldenstrom macroglobulinaemia, follicular lymphoma, and multiple myeloma; it has already been approved for relapsed or refractory mantle cell lymphoma in the US, Brazil, the UAE, and Qatar.

Previous Post

Camargo to Acquire Montreal-based InSymbiosis

Next Post

Janssen partners with nference for AI-based drug development

Related Posts

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
Next Post
AI-based drug development

Janssen partners with nference for AI-based drug development

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In